Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550428 | 0.84 | ULK1 (0.41) | ULK1GRIN1ALOX15XDHNR4A2 | |
| SCHEMBL7658321 | 0.82 | ALOX15 (0.41) | ULK1ALOX15 | |
| SCHEMBL7550281 | 0.81 | ULK1 (0.35) | ULK1GRIN1ALOX15NR4A2RHEB | |
| SCHEMBL7550279 | 0.81 | ULK1 (0.35) | ULK1GRIN1ALOX15NR4A2RHEB | |
| SCHEMBL9433015 | 0.77 | GRIN1 (0.66) | ULK1GRIN1ALOX15NR4A2CYP1A2 | |
| SCHEMBL24020832 | 0.74 | ULK1 (0.53) | ULK1GRIN1ALOX15NR4A2CYP1A2 | |
| SCHEMBL7650520 | 0.74 | ULK1 (0.47) | ULK1GRIN1ALOX15XDHNR4A2 | |
| SCHEMBL20535730 | 0.74 | ULK1 (0.47) | ULK1GRIN1ALOX15XDHNR4A2 | |
| SCHEMBL30310577 | 0.74 | ULK1 (0.53) | ULK1GRIN1ALOX15NR4A2CYP1A2 | |
| SCHEMBL24020651 | 0.74 | GRIN1 (0.50) | ULK1GRIN1NR4A2CYP1A2RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495587-B1 | TREATING A DAMAGE TO THE CENTRAL NERVOUS SYSTEM INDUCED BY AN ISCHEMIC OR HYPOXIC CONDITION AND STROKE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-0657427-B1 | Tricyclic indole-2-carboxylic acid derivatives being selective antagonists of the NMDA receptor | SUMITOMO PHARMA (JP) | 2002-06-19 | — | — | EP | disclosed |
| EP-1163220-A1 | TRICYCLIC INDOLE-2-CARBOXYLIC ACID COMPOUND USED AS NMDA RECEPTOR ANTAGONIST | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056711-A1 | TRICYCLIC INDOLE-2-CARBOXYLIC ACID COMPOUND USED AS NMDA RECEPTOR ANTAGONIST | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2000-09-28 | — | — | WO | disclosed |
| US-5496843-A | Tricyclic indole-2-carboxylic acid derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0657427-A1 | Tricyclic indole-2-carboxylic acid derivatives being selective antagonists of the NMDA receptor | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-06-14 | — | — | EP | disclosed |